Madill Morgann, Aggarwal Arpit, Madabhushi Anant, Erickson Britt K, Nelson Andrew C, Lou Emil, Bazzaro Martina
Masonic Cancer Center and Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, MA 55455, USA.
Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, GA 30322, USA.
Mol Ther Oncol. 2025 May 24;33(2):201001. doi: 10.1016/j.omton.2025.201001. eCollection 2025 Jun 18.
Epithelial ovarian cancer remains one of the deadliest gynecologic malignancies, with late-stage diagnosis, high recurrence rates, and resistance to platinum-based chemotherapy contributing to poor survival outcomes. Central to the effective management of ovarian cancer is the thorough evaluation of diagnostic and prognostic indicators. Critical determinants encompass the extent of the tumor; its stage and grade; and level of the circulating biomarker, CA-125. Additional tumor cell-centric factors such as BRCA1/2 mutation status, homologous recombination deficiency, and folate receptor-alpha (FRα) protein levels inform initial treatment and maintenance strategies. Unfortunately, these markers alone cannot fully predict outcomes or significantly improve survival rates. This review emphasizes the body of data suggesting that both quantitative and qualitative metrics of tumor stroma play a crucial role in the prognosis and outcomes of epithelial ovarian cancer. We examine quantitative and qualitative metrics such as stromal proportion, tumor density, stiffness, and texture. We explore how artificial intelligence (AI) tools advance the measurement of these parameters, offering unprecedented opportunities to integrate stromal biomarkers into clinical decision-making. By synthesizing emerging evidence, we propose a framework for leveraging stromal properties-individually and in combination-as novel prognostic indicators to improve outcomes for patients with ovarian cancer.
上皮性卵巢癌仍然是最致命的妇科恶性肿瘤之一,晚期诊断、高复发率以及对铂类化疗的耐药性导致了较差的生存结果。对卵巢癌进行有效管理的核心是对诊断和预后指标进行全面评估。关键决定因素包括肿瘤范围、分期和分级以及循环生物标志物CA-125的水平。其他以肿瘤细胞为中心的因素,如BRCA1/2突变状态、同源重组缺陷和叶酸受体-α(FRα)蛋白水平,为初始治疗和维持策略提供依据。不幸的是,仅这些标志物无法完全预测预后或显著提高生存率。本综述强调了大量数据表明,肿瘤基质的定量和定性指标在上皮性卵巢癌的预后和结果中起着关键作用。我们研究了诸如基质比例、肿瘤密度、硬度和质地等定量和定性指标。我们探讨了人工智能(AI)工具如何推进这些参数的测量,为将基质生物标志物整合到临床决策中提供了前所未有的机会。通过综合新出现的证据,我们提出了一个框架,利用基质特性——单独和组合使用——作为新的预后指标,以改善卵巢癌患者的预后。